GSK announces succession plan for cfo

Simon Dingemans joins from Goldman Sachs

Simon Dingemans has been named as chief financial officer designate and executive director of GlaxoSmithKline (GSK) from 4 January 2011. He will succeed Julian Heslop, who is to retire as chief financial officer and executive director of the company at the end of March 2011.

Dingemans joins the pharmaceutical firm from Goldman Sachs where he is currently managing director and partner. He has more than 25 years’ experience in investment banking, including most recently as leader of Goldman Sachs' European M&A business and before that as head of UK Investment Banking. During this time he has built relationships and offered strategic advice across multiple industry sectors, including pharmaceuticals and consumer healthcare.

Dingemans has worked closely with GSK for many years, most recently helping to establish ViiV Healthcare, a specialist HIV company.

Andrew Witty, chief executive of GSK, said: ‘Simon's appointment as cfo reflects the need for GSK to operate with both creativity and continued financial discipline. He will also be responsible for delivering cost savings from our global restructuring programme and implementing further measures to simplify our operational model.’

You may also like

Manufacturing

Thermo Fisher Scientific doubles down on investment in Asia

New and expanded Bioprocess Design Centres will provide local expertise, advanced technologies and tailored support for biopharma innovators throughout the region
Finance

EIB and Angelini Ventures launch €150m fund to boost European biotech, medtech and digital health startups

The EIB and Angelini Ventures will co-invest €150 million to scale innovative European healthtech companies. The deal marks the EIB’s first partnership with a corporate venture capital fund in the healthcare sector
Finance

Fresh capital flows into neurodegeneration, cancer and vascular-access developers

A string of funding rounds and strategic financing deals across Europe’s life-sciences sector is breathing new life into companies working on high-need treatments — from neurodegeneration to cancer and dialysis access
Finance

Budget 2025: EY comments on the industrial impact of the Autumn Budget

Mark Minihane, UK&I Industrials and Energy Tax Leader for EY, comments on the industrial implications of the Chancellor’s Autumn Budget
Finance

Response to Budget from the Institution of Chemical Engineers (IChemE)

On 26 November, the Chancellor of the Exchequer, the Rt Hon Rachel Reeves MP, delivered the 2025 UK Autumn Budget
Research & Development

Gates Foundation awards Keltic Pharma $1.3 million for malaria drug research

The University of Glasgow spin-out's malaria programme is moving towards IND enablement within the next 12 months and is designed to deliver a single-dose cure — a potential breakthrough in efforts to combat one of the world’s most lethal diseases
You need to be a subscriber to read this article.
Click here to find out more.
Finance

UK bioindustry edges toward a critical turning point after the autumn budget

New tax breaks promise to fuel UK biotech scale-ups, but escalating workspace rates threaten to slow the momentum
Subscribe now